OncoMatch/Clinical Trials/NCT04570423
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Is NCT04570423 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Eflapegrastim and Chemotherapy for solid tumors.
Treatment: Eflapegrastim · Chemotherapy — The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: filgrastim (filgrastim)
previous exposure to filgrastim (within 7 days)
Cannot have received: pegfilgrastim (pegfilgrastim)
pegfilgrastim (within 14 days)
Cannot have received: granulocyte colony stimulating factor
other granulocyte colony stimulating factor (G-CSF) products in clinical development within 2 weeks prior to the administration of study drug (eflapegrastim)
Cannot have received: bone marrow or hematopoietic stem cell transplant
prior bone marrow or hematopoietic stem cell transplant
Cannot have received: spinal radiation therapy
spinal radiation therapy within 30 days prior to study enrollment
Cannot have received: investigational drugs, biologics or devices
used any investigational drugs, biologics or devices within 30 days prior to study treatment or plans to use any of these during the study
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
ECHO or MUGA within 14 days of Screening if receiving a cardiotoxic therapy and have a cardiac ejection fraction of >50%
adequate hematological, renal, and hepatic function; echocardiogram (ECHO) or multigated acquisition (MUGA) within 14 days of Screening if receiving a cardiotoxic therapy and have a cardiac ejection fraction of >50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- New York Medical College · Valhalla, New York
- Carolinas Medical Center/ Levine Children's Hospital · Charlotte, North Carolina
- Levine Children's Health · Charlotte, North Carolina
- University Hospitals Cleveland Medical Center · Cleveland, Ohio
- UT MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify